7,762 results match your criteria: "Seminoma"

Purpose Of Review: Chemotherapy offers excellent long-term survival rates for men with clinical stage II germ cell tumours. However, in this predominantly younger population, chemotherapy is associated with long-term adverse effects. Primary retroperitoneal lymph node dissection (RPLND) may serve as an alternative treatment option, preserving oncological safety while potentially reducing adverse effects in men with limited retroperitoneal disease.

View Article and Find Full Text PDF

Histone variant H3.5 in testicular cell differentiation and its interactions with histone chaperones.

Sci Rep

December 2024

Clinical Molecular Genetics and Epigenetics, Faculty of Health, Centre for Biomedical Education & Research (ZBAF), Witten/Herdecke University, Alfred-Herrhausen-Str. 50, 58448, Witten, Germany.

Testicular cell differentiation is a highly regulated process, essential for male reproductive health. The histone variant H3.5 is apparently a critical player in this intricate orchestra of cell types, but its regulation and function remains poorly understood.

View Article and Find Full Text PDF

Testicular cancer is one of the leading malignancies affecting young men, with germ cell tumors (GCTs) being the most prevalent type. These tumors are classified into two main subtypes: seminomas and non-seminomatous germ cell tumors (NSGCTs), with the latter known for their higher likelihood of metastasis. Early detection through imaging and tumor markers like alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin (HCG) is crucial for favorable outcomes.

View Article and Find Full Text PDF

Contemporary surgical management of testicular seminoma.

Transl Cancer Res

November 2024

Division of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Testicular cancer is the most commonly diagnosed cancer among young men in the United States. Seminoma comprises a little over half of all testicular germ cell neoplasms. After radial inguinal orchiectomy, management of seminoma is dictated by tumor stage and risk stratification.

View Article and Find Full Text PDF

We report the case of a 39-year-old patient who complains about loss of libido and erectile dysfunction. Hormonal diagnosis revealed hypergonadotropic hypogonadism suggesting a primitive testicular cause. Testicular examination, testicular ultrasounds and abdomen-pelvis CT scan made it possible to suspect a right testicular tumor.

View Article and Find Full Text PDF

Seminoma is a malignant germ cell tumor that primarily develops in the testis but can occur in other extragonadal areas, most commonly the mediastinum and retroperitoneum. While generally offering a favorable prognosis, seminomas can sometimes clinically present with misleading characteristics resulting in delayed diagnosis. In this article, we report the case of a 31-year-old male diagnosed with grade IIIC intermediate risk testicular seminoma cTxN3M1bSx, who presented initially with a palpable cervical mass.

View Article and Find Full Text PDF
Article Synopsis
  • Testicular cancer is the most common cancer in young adult men, with high survival rates of around 99% for early-stage and over 80% for advanced-stage cases.
  • Traditional tumor markers like AFP, β-hCG, and LDH have limited sensitivity and can give false positives, leading to a need for new biomarkers.
  • MicroRNA-371a-3p shows promising results in diagnosing germ cell tumors with around 90% sensitivity and may help in treatment decisions, while ongoing clinical trials are validating its effectiveness and exploring other biomarkers like ctDNA and CTCs.
View Article and Find Full Text PDF

THE OUTCOMES OF ONCO-TESE AT THE TIME OF RADICAL ORCHIECTOMY.

Urology

December 2024

Sexual & Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Objectives: To evaluate outcomes of onco-testis sperm extraction (TESE) and to define potential predictors of successful surgical sperm retrieval (SSR).

Methods: For this study, we examined all men (i) diagnosed with a testicular mass, (ii) who had azoospermia, and (iii) who underwent a radical orchiectomy and onco-TESE. Our institutional database of testicular cancer (TCA) patients was reviewed.

View Article and Find Full Text PDF

Testicular cancer accounts for approximately 5 % of all urologic cancers. The most common histopathological diagnosis of testicular neoplastic lesions are germ cell tumors (90-95 % of cases), among which the majority of cases are seminomas, the most common malignant tumors among men aged 15-44. For better clinical diagnosis and treatment, it is important to understand the molecular mechanisms of tumor formation.

View Article and Find Full Text PDF

A 30-year-old Hispanic male was admitted to the medicine service for a growing left testicular and pan-abdominal mass. His prior medical and surgical history was unremarkable. CT imaging showed a retroperitoneal and intraperitoneal mass.

View Article and Find Full Text PDF

The treatment of patients affected by a teratoma with somatic-type malignancy (STM) is challenging, since they are characterized by a poor prognosis, due to chemoresistance to standard cisplatin-based regimens. Only five more case reports were described for melanomatous STM and for which there are no data available for efficacy evidences of immune checkpoint inhibitors in this setting. Here we report the case of a patient with an initial diagnosis of mediastinal pure seminoma at the first biopsy.

View Article and Find Full Text PDF
Article Synopsis
  • - Testicular cancer, though a rare adult cancer, is rising in incidence and primarily consists of germ cell tumors, subdivided into seminomas and non-seminomas, with notable risk factors such as cryptorchidism and family history.
  • - Diagnosis involves a detailed clinical evaluation, imaging studies, and tumor markers, while orchidectomy (surgical removal of the testicle) is the standard treatment, often followed by chemotherapy to prevent recurrence.
  • - Education on testicular self-examination and fertility preservation options pre-surgery is crucial, along with ongoing multidisciplinary follow-up to enhance treatment outcomes and patients' quality of life.
View Article and Find Full Text PDF

French AFU Cancer Committee Guidelines - Update 2024-2026: Testicular germ cell cancer.

Fr J Urol

November 2024

Comité de Cancérologie de l'Association Française d'Urologie, groupe organes génitaux externes, Maison de l'Urologie, 11, rue Viète, 75017 Paris, France; Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France.

Article Synopsis
  • The objective of the review is to update guidelines for managing testicular germ cell tumors (TGT) based on recent literature from 2022.
  • Initial diagnosis involves clinical exam, serum marker levels (AFP, hCG, LDH), and imaging techniques like ultrasound and CT scans; treatment starts with inguinal orchiectomy which helps in defining the tumor stage and treatment approach.
  • For specific stages of the tumors, treatment strategies vary, including surveillance for stage I seminomas, risk-adapted options for stage I non-seminomatous tumors, and chemotherapy for metastatic cases, with additional measures like radiotherapy for certain seminoma stages.
View Article and Find Full Text PDF

Exploiting potential molecular compounds for treating testicular seminoma by targeting immune related genes.

Cell Commun Signal

November 2024

Department of Urology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Article Synopsis
  • Advanced seminoma patients face a serious challenge with up to 30% exhibiting resistance to cisplatin, leading to a high mortality risk, and limited treatment options beyond traditional therapies like chemotherapy and radiotherapy.
  • A study utilized advanced statistical methods to identify immune-related genes, leading to the development of a prognostic signature that predicts patient survival more accurately than existing risk factors.
  • Results indicated that patients identified as high-risk had significantly lower progression-free survival, and certain molecular compounds could effectively target the identified genes, suggesting potential for immunotherapy in these patients.
View Article and Find Full Text PDF

Radiation therapy for stage IIA/IIB seminomas: Back to the future?

Radiother Oncol

January 2025

Department of Radiotherapy, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.

Article Synopsis
View Article and Find Full Text PDF
Article Synopsis
  • The case report details a rare occurrence of a postpubertal-type teratoma in a 48-year-old male, which appeared as a late recurrence of a previously diagnosed seminoma following testicular surgery six years earlier.
  • Imaging tests showed a retroperitoneal tumor with unusual characteristics, leading to a biopsy that indicated a high-grade malignant tumor, prompting neoadjuvant chemotherapy that helped shrink the tumor before surgical removal.
  • Further analysis revealed that the original seminoma diagnosis overlooked a mixed germ cell tumor component, underscoring the need for comprehensive histological evaluations in testicular germ cell tumors to better inform prognosis and treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • Carboplatin is an effective and safer alternative to cisplatin for treating stage I seminoma, minimizing risks like nephrotoxicity and ototoxicity.
  • A case involved a 48-year-old man who experienced hematuria and acute kidney injury after receiving adjuvant carboplatin following surgery for testicular seminoma.
  • The acute kidney injury resolved after conservative management and the removal of a blood clot during cystoscopy, with imaging indicating potential ureteral obstruction.
View Article and Find Full Text PDF
Article Synopsis
  • - Myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) are autoimmune diseases that can develop after infections, vaccinations, or even in rare cases linked to cancer (paraneoplastic context).
  • - The article discusses a case where a patient developed subacute inflammatory myelopathy after their fourth mRNA COVID-19 vaccine dose, later diagnosed with MOGAD and a metastatic seminoma, and treated successfully.
  • - An analysis of 72 cases showed most MOGAD instances post-vaccination occurred after the first dose with a typical onset around 19 days later, highlighting the possibility that vaccination may activate underlying autoimmune conditions rather than directly cause them, as seen in this patient.
View Article and Find Full Text PDF
Article Synopsis
  • Embryonal carcinoma (EC) is a highly malignant subtype of testicular germ cell tumors that shares characteristics with embryonic stem cells, but the reasons for its aggression are not well understood.
  • This study used single-cell RNA sequencing on non-seminoma samples and found that the protein SERPINB9 is highly expressed in metastatic EC cells, and its knockdown leads to reduced cell migration and drug resistance.
  • The research suggests that SERPINB9 is crucial for maintaining cancer stemness and influences key signaling pathways, making it a potential target for developing new cancer therapies.
View Article and Find Full Text PDF
Article Synopsis
  • MicroRNAs (miRNAs) such as miR-99a-5p, miR-100-5p, and miR-125b-5p are typically downregulated in malignant germ cell tumors (GCTs), leading to potential issues in tumor growth and behavior.
  • In this study, researchers used quantitative RT-PCR and treatments like 5-azacytidine to investigate the dysregulation of these miRNAs and their effects on cancer cell growth in different types of malignant GCTs.
  • They found that replenishing levels of miR-100-5p and miR-125b-5p inhibited the growth of GCT cells and altered related signaling pathways, suggesting a potential therapeutic approach
View Article and Find Full Text PDF

Optimal Treatment Strategies for Early-Stage Primary Mediastinal Germ Cell Tumors.

Ann Thorac Surg

November 2024

Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA. Electronic address:

Article Synopsis
  • The study examines survival outcomes for patients with early-stage primary mediastinal germ cell tumors, comparing surgery and chemotherapy treatment options.
  • Among seminomas, no significant survival difference was found between patients receiving chemotherapy alone and those undergoing surgery; however, for non-seminomatous tumors, surgery showed improved 5-year survival rates.
  • The findings suggest that for non-seminomatous germ cell tumors, a combination of surgery and other treatments leads to better survival compared to chemotherapy alone, while seminomas can achieve similar outcomes with chemotherapy alone.
View Article and Find Full Text PDF